BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 32900796)

  • 1. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
    Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
    Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
    Rosell R; Jantus-Lewintre E; Cao P; Cai X; Xing B; Ito M; Gomez-Vazquez JL; Marco-Jordán M; Calabuig-Fariñas S; Cardona AF; Codony-Servat J; Gonzalez J; València-Clua K; Aguilar A; Pedraz-Valdunciel C; Dantes Z; Jain A; Chandan S; Molina-Vila MA; Arrieta O; Ferrero M; Camps C; González-Cao M
    Cell Commun Signal; 2024 Jun; 22(1):324. PubMed ID: 38867255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity and resistance to KRAS
    Ye W; Lu X; Qiao Y; Ou WB
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Acquired Resistance to KRAS
    Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
    Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
    Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH
    Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PI3Kα overcomes resistance to KRas
    Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
    Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
    Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
    Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR Blockade Reverts Resistance to KRAS
    Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
    Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired Resistance to KRAS
    Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
    N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
    Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
    Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The KRAS-G12C inhibitor: activity and resistance.
    Liu J; Kang R; Tang D
    Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    Manabe T; Bivona TG
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell Type-specific Adaptive Signaling Responses to KRAS
    Solanki HS; Welsh EA; Fang B; Izumi V; Darville L; Stone B; Franzese R; Chavan S; Kinose F; Imbody D; Koomen JM; Rix U; Haura EB
    Clin Cancer Res; 2021 May; 27(9):2533-2548. PubMed ID: 33619172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
    Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
    Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
    Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
    Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of Wild-type
    Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
    Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting KRAS
    Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
    Drugs; 2024 May; 84(5):527-548. PubMed ID: 38625662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.